Emerging nanotaxanes for cancer therapy

Area of Science:

• Oncology
• Nanotechnology
• Materials Science

Background:

• Clinical use of taxanes (paclitaxel, docetaxel, cabazitaxel) is limited by off-target effects, poor release, and resistance.
• Nanoparticulate drug delivery systems (nano-DDSs) and novel biomaterials have enabled development of high-efficiency, low-toxicity nanotaxanes.

Purpose of the Study:

• To review advancements in nanotaxane-targeted delivery and stimuli-responsive nano-DDSs.
• To overview nanotherapeutics combating tumor resistance and metastasis.
• To discuss synergistic therapy strategies and oral nanotaxanes.

Main Methods:

• Literature review of preclinical and clinical studies on nanotaxanes.
• Analysis of emerging nanotherapeutics and combination therapies.
• Discussion of recent developments in oral nanotaxane formulations.

Main Results:

• Nanotaxanes show promise in improving drug delivery and reducing toxicity compared to conventional taxanes.
• Stimuli-responsive nano-DDSs enhance targeted delivery and therapeutic efficacy.
• Synergistic therapies combining nanotaxanes with other modalities show potential against tumor resistance and metastasis.

Conclusions:

• Nanotaxanes represent a significant advancement in cancer therapy, addressing limitations of traditional taxanes.
• Targeted delivery and stimuli-responsive systems are key to maximizing nanotaxane efficacy.
• Combination strategies and novel formulations like oral nanotaxanes offer promising avenues for future cancer treatment.